Skip to Main Content

NANETS

  • About
    • Mission
    • Board of Directors
    • Committees
    • NANETS Presidents
    • Lifetime Achievement
    • Outstanding Service
    • History
    • Diversity Statement
  • Education
    • Upcoming Symposia
    • Regional NET Education
    • Conference Archives
    • NETMed Webinars
    • About NETs
  • Research
    • Abstracts
    • Research Grants
    • Grant Recipients
  • Guidelines
  • Resources
    • Grant Resources
    • Employment Postings
    • Clinical Trials
    • Member DirectoryMember Directory
    • NET Around the World
    • Patient Resources
    • COVID-19 Resource Page
  • News
    • NET eNews
    • Media
    • PancreasPancreas
    • Photo Gallery
  • Membership
    • Member Benefits
    • Member Categories
    • Join NOW
    • Code of Conduct
  • 2020

  • 2019

  • 2018

  • 2017

  • 2016

  • 2015

  • 2014

  • 2013

  • 2012

  • 2011

  • 2010

  • 2009

BT01 – Targeting Glycogen Synthase Kinase-3 as a Therapy for Pediatric Neuroendocrine Tumor

Published in 2014 Listed under BT

Download

Balamurugan

BT02 – Drug Discovery for Atypical Pulmonary Carcinoid Using a Library of Targeted Agents

Published in 2014 Listed under BT

Download

Chong

BT03 – Pathologic Classification of Pulmonary Carcinoid Cell Lines

Published in 2014 Listed under BT

Download

Chong

BT04 – Whole Exome Sequencing Identifies Somatic ATRX Mutations in Pheochromocytomas and Paragangliomas

Published in 2014 Listed under BT

Download

Fishbein

BT05 – Cadherin 17 is Frequently Expressed by “Sclerosing Variant” Pancreatic Neuroendocrine Tumor

Published in 2014 Listed under BT

Download

Johnson

BT06 – Molecular Profiling of Small Intestinal Neuroendocrine Tumour

Published in 2014 Listed under BT

Download

Karpathakis

BT07 – Induction of Serotonin Production in Human Pancreatic Neuroendocrine Tumors by Tryptophan Hydroxylase-1

Published in 2014 Listed under BT

Download

Kelly

BT08 – Targeted-Alpha-Therapy with Astatine-211-Meta-Astatobenzylguanidine ( 211 At-MABG) in the Treatment of Pheochromocytoma

Published in 2014 Listed under BT

Download

Makvandi

BT09 – A Practical Method to Determine the Site of Unknown Primary in Metastatic Neuroendocrine Tumors

Published in 2014 Listed under BT

Download

Maxwell

BT10 – Receptor for Hyaluron-Mediated Motility Isoform B Protects Pancreatic Neuroendocrine Tumors From Anoikis

Published in 2014 Listed under BT

Download

Pages

BT11 – Exploration and Targeting of Neuroendocrine Cancer Tumorigenic Signal Transduction

Published in 2014 Listed under BT

Download

Pozo

BT12 – Autophagy Activation, a Survival Mechanism for pNETs Treated with mTOR Inhibitors

Published in 2014 Listed under BT

Download

Thomas

BT13 – Molecular Profiling of Advanced Stage Neuro Endocrine Tumors (NETs): The Fox Chase Cancer Center (FCCC) Experience

Published in 2014 Listed under BT

Download

Vijayvergia

C01 – Incidence, Prevalence and Survival of Patients with Small Bowel Neuroendocrine Tumors (MGC) Excluding Appendiceal Tumors: A Northern Ireland (NI) Study Over 25 years

Published in 2014 Listed under Clinical

Download

Ardill

C02 – Poor Prognosis in Spontaneous Gastrinoma When Additional Hormones and Peptides are Secreted

Published in 2014 Listed under Clinical

Download

Ardill

C03 – Health-Related Quality of Life (HRQL) in Patients With Uncontrolled Neuroendocrine Tumor (NET) Symptoms

Published in 2014 Listed under Clinical

Download

Beaumont

C04 – Long Term Effects of Surgical Resection of Pheochromocytoma or Paraganglioma on Body Weights: A Retrospective Cohort Study

Published in 2014 Listed under Clinical

Download

Bennett

C05 – Theranostics with I-131/I-123 Meta-Iodobenzylguanidine (MIBG) in Stage IV Advanced Malignant Neuroendocrine Tumors

Published in 2014 Listed under Clinical

Download

Campeau

C06 – Antitumor Effects with Lanreotide Autogel/Depot (LAN) in Patients with Metastatic Enteropancreatic (EP) Neuroendocrine Tumors (NETs): Interim Results of the CLARINET Extension Study

Published in 2014 Listed under Clinical

Download

Caplin

C07 – Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) and the Role of Somatostatin Analogs

Published in 2014 Listed under Clinical

Download

Chauhan

C08 – Chemotherapy for Locally Advanced and Metastatic Pulmonary Carcinoid Tumors

Published in 2014 Listed under Clinical

Download

Chong

C09 – A Phase II Study of Axitnib in Advanced Carcinoid Tumors

Published in 2014 Listed under Clinical

Download

Cives

C10 – Use of Molecular Profiling to Guide Treatment Decisions in Patients with Neuroendocrine Tumors

Published in 2014 Listed under Clinical

Download

Cutler

C11 – The Prognostic Significance of Lymph Node Ratio in Carcinoid Tumors

Published in 2014 Listed under Clinical

Download

Flatow

C12 – Response to Capecitabine and Temozolomide in an Adolescent Female with Metastatic, Non-functional Pancreatic Neuroendocrine Tumor

Published in 2014 Listed under Clinical

Download

Gilbert

C13 – Small Intestine Neuroendocrine Tumors: Frequently of Unrecognized Primary Site and Multifocal

Published in 2014 Listed under Clinical

Download

Javeed

C14 – Elevated Serum Pancreastatin is an Indicator of Hepatic Metastasis in Patients with Small Bowel Neuroendocrine Tumors

Published in 2014 Listed under Clinical

Download

Khan

C15 – A Multi-Gene Transcript Blood Molecular Signature for Gut Neuroendocrine Tumors (NETs) Delineates Surgical Efficacy

Published in 2014 Listed under Clinical

Download

Kidd

C16 – Prognostic Significance of the Extent of Lymph Node Metastases in Small Intestinal Neuroendocrine Tumors

Published in 2014 Listed under Clinical

Download

Kim

C17 – Comparison of the Effectiveness of 68Ga-DOTATATE PET/CT and 111In-Octreotide SPECT in Patients with Somatostatin Positive Neuroendocrine Tumor

Published in 2014 Listed under Clinical

Download

Kumar

C18 – DNA-repair Defects in Pancreatic Neuroendocrine Tumors and Potential Clinical Applications

Published in 2014 Listed under Clinical

Download

Liu

C19 – Long-term Outcomes of Surgical Management of Pancreatic Neuroendocrine Tumors with Liver Metastases

Published in 2014 Listed under Clinical

Download

Partelli

C20 – A Prospective, Multi-Institutional Phase II Study of Pazopanib and Depot Octreotide in Advanced, Well-Differentiated Neuroendocrine Tumors

Published in 2014 Listed under Clinical

Download

Phan

C21 – Prognostic Significance of CDKN1B (p27) Expression in Gastroenteropancreatic Neuroendocrine Tumors

Published in 2014 Listed under Clinical

Download

Qian

C22 – Evaluation of the Features of Long Term Hematologic Toxicity in Neuroendocrine Patients Treated with Peptide Receptor Radionuclide Therapy(PRRT)

Published in 2014 Listed under Clinical

Download

Richter

C23 – Weight Gain After Acid Control in Zollinger Ellison Syndrome

Published in 2014 Listed under Clinical

Download

Riff

C24 – Phase I, Open-Label, Randomized, Pharmacokinetic/Pharmacodynamic (PK/PD) Study of Octreotide Subcutaneous (sc) Depot Versus Octreotide Long-Acting Repeatable (OCT-LAR) in Healthy Volunteers

Published in 2014 Listed under Clinical

Download

Roberts

C25 – Phase I, Open-Label, Randomized, Bioequivalence Study of Octreotide (OCT) Long-Acting Repeatable (LAR) Reconstituted in a New Vehicle (NV) vs OCT LAR 30 mg (current vehicle)

Published in 2014 Listed under Clinical

Download

Roberts

C26 – Quality of Life (QoL) with Lanreotide Autogel/Depot (LAN) vs. Placebo in Patients with Enteropancreatic Neuroendocrine Tumors: Results From the CLARINET Core Study

Published in 2014 Listed under Clinical

Download

Ruszniewski

C27 – Treatment Satisfaction, Symptom Control, and Quality of Life (QoL) with Lanreotide Autogel/Depot (LAN) in Neuroendocrine Tumor (NET) Patients with Carcinoid Syndrome (CS): Results From the SymNET Study

Published in 2014 Listed under Clinical

Download

Ruszniewski

C28 – Ki 67 and/or Mitotic Count in the Czech Neuroendocrine Tumour Registry

Published in 2014 Listed under Clinical

Download

Sedlackova

C29 – Octreotide LAR Among Elderly Patients With Neuroendocrine Tumors: A Survival Analysis of SEER-Medicare Data

Published in 2014 Listed under Clinical

Download

Shen

C30 – Pancreastatin Predicts Survival in Neuroendocrine Tumors

Published in 2014 Listed under Clinical

Download

Sherman

C31 – Efficacy of Octreotide Long-Acting Repeatable (OCT) From the Phase III RADIANT-2 Study in Patients With Advanced Neuroendocrine Tumors (NET): A Post-Hoc Analysis of the Placebo (PBO) Arm With Updated Survival Data

Published in 2014 Listed under Clinical

Download

Strosberg

C32 – Real-World First-Line Treatment Patterns Among US Carcinoid Syndrome Patients

Published in 2014 Listed under Clinical

Download

Sun

C33 – The Healthcare and Economic Impact of Diarrhea on US Patients with Carcinoid Syndrome

Published in 2014 Listed under Clinical

Download

Broder

C34 – Preoperative Metyrosine Improves Cardiovascular Outcomes For Patients Undergoing Surgery For Pheochromocytoma and Paraganglioma

Published in 2014 Listed under Clinical

Download

Wachtel

C35 – Adjuvant Intraoperative Post-Dissection Tumor Bed Chemotherapy – A Novel Approach in Treating Midgut Neuroendocrine Tumors

Published in 2014 Listed under Clinical

Download

Wang

C36 – In Vitro Chemotherapy Profiling of Well-Differentiated Midgut Neuroendocrine Tumors (NETs) Based on Individual Patient Tumor Biomarkers Analysis

Published in 2014 Listed under Clinical

Download

Wang

C37 – Reappraisal of Lymphatic Mapping for Midgut Neuroendocrine Patients Undergoing Cytoreductive Surgery

Published in 2014 Listed under Clinical

Download

Wang

C38 – Telotristat Etiprate (TE) in a Subset of Patients with Carcinoid Heart Disease Included in Two Phase 2 Trials for Carcinoid Syndrome

Published in 2014 Listed under Clinical

Download

Wheeler

C39 – Telotristat Etiprate in a Subset of Carcinoid Syndrome Patients who have High Levels of Urinary 5-hydroxyindoleacetic Acid and Frequent Flushing

Published in 2014 Listed under Clinical

Download

Wheeler

C40 – Phase 1 Expansion Study of an Oral TORC1/TORC2 Inhibitor (CC-223) in Non-Pancreatic Neuroendocrine Tumors (NET)

Published in 2014 Listed under Clinical

Download

Wolin

C41 – Everolimus (EVE) for the Treatment of Advanced Pancreatic Neuroendocrine Tumors (pNET): Final Overall Survival (OS) Results of a Randomized, Double-Blind, Placebo (PBO)-Controlled, Multicenter Phase 3 Trial (RADIANT-3)

Published in 2014 Listed under Clinical

Download

C42 – Early Recurrence of Carcinoid Valvulopathy After Valve Replacement

Published in 2014 Listed under Clinical

Download

Zacks

C43 – Clinical and Immunohistochemical Features of High Grade Neuroendocrine Neoplasia of the Gastrointestinal Tract

Published in 2014 Listed under Clinical

Download

Zemek

O01 – Neuroendocrine tumor (NET) Impact on Quality of Life (QOL) Patient Experience From the First Global NET Patient Survey: A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals

Published in 2014 Listed under Other

Download

Goldstein

OT02 – Netter-1: First Pivotal Multicenter Phase III Study Evaluating 177 Lu-dotatate in Midgut Neuroendocrine Tumors

Published in 2014 Listed under OT

Download

Sierra

NANETS

136 Everett Rd | Albany, NY 12205
(650) 7NANETS | staff@nanets.net

Twitter Facebook LinkedIn
  • Privacy Policy
  • |
  • Site Map

Copyright ©2021 ADG. All Rights Reserved | Web Design & Development by ADG Creative, a division of ADG.
ADG is a certified Women Owned Business.